top of page

NCI-2022-01323

A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer


This is a research study that's trying out a new kind of medicine for the first time. The medicine is called RLY-2608, and it's meant to target a specific protein called PI3Kα. This protein is found in some tumors (abnormal growths) in the body. The study is being done with two groups of people: The first group has advanced tumors. These people will be given only the new medicine, RLY-2608, to see how well it works on its own. The second group has a specific type of advanced breast cancer. They will receive a combination of the new medicine, RLY-2608, and another treatment called Fulvestrant. Fulvestrant is a medicine used to treat breast cancer. The goal of this study is to find out if RLY-2608 is safe to use in people and whether it can help treat advanced tumors and breast cancer. They'll be looking at how well the medicine works in shrinking the tumors, how the patients' bodies respond, and how the patients feel during the treatment.

Advanced: Advanced breast cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

NCI-2022-01323

Clinical Trial Site: Columbia


To see all available clinical trials click here.



Recent Posts

See All

NCI-2023-06503

An open-label, single-arm, Phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of LS301-IT in female patients undergoing partial mastectomy and sentinel lymph node biopsy (SLNB)

NCI-2022-02453

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer Doctors are conducting a study to test the safety and effectiveness of a new medicine called

NCI-2022-07265

EAY191-N2 Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 A ComboMATC

Comments


bottom of page